Compare Home Depot Inc (HD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs TG Therapeutics Inc — how do they compare? Home Depot Inc trades at $330.49 (market cap $332.08B), while TG Therapeutics Inc trades at $54.25 (market cap $8.26B). The key difference: Home Depot Inc is far larger — about 40.2× TG Therapeutics Inc's market cap, and Home Depot Inc pays a 2.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HD | TGTX | |
|---|---|---|
Market Cap | $332.08B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $59.06 |
52-Week Low | $297.51 | $26.39 |
Enterprise Value | $393.64B | $8.50B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $331.84, down 2.07% on the day, as the stock faces technical bearish pressure with mixed earnings performance. The company reported Q1 2026 EPS of $3.43, beating expectations, but missed in Q3 2025. Revenue reached $159.51B in 2025 with strong profitability metrics including 8.41% net margin and 128.38% ROE. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $370.59 price target.
HD presents a compelling long-term investment case with strong fundamentals and analyst support, though near-term headwinds include weakening big-ticket demand and margin pressure. The stock's current discount to consensus target offers potential upside, but investors should monitor housing market trends and consumer spending patterns that impact home improvement demand.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
